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ABSTRACT
Objective: To investigate T cell and antibody immunity to
Epstein–Barr virus (EBV) in multiple sclerosis (MS).
Methods: Immunoglobulin G (IgG) immunity to EBV
nuclear antigen 1 (EBNA1) and viral capsid antigen was
measured by enzyme linked immunosorbent assays, and T
cell immunity was assessed using enzyme linked
immunospot assays to measure the frequency of
peripheral blood mononuclear cells (PBMC) producing
interferon c in response to autologous EBV infected B cell
lymphoblastoid cell lines (LCL) in 34 EBV seropositive
healthy subjects and 34 EBV seropositive patients with
MS who had not received immunomodulatory therapy in
the previous 3 months.
Results: Patients with MS had increased levels of anti-
EBNA1 IgG but a decreased frequency of LCL specific T
cells compared with healthy subjects. Using purified
populations of CD4
+ T cells and CD8
+ T cells, we showed
that the LCL specific response resides predominantly in
the CD8
+ population, with a frequency 5–7-fold higher
than in the CD4
+ population. The decreased CD8
+ T cell
response to LCL in MS was not caused by decreased HLA
class I expression by LCL, and LCL from MS patients could
be killed normally by HLA matched EBV specific cytotoxic
CD8
+ T cell clones from healthy subjects. Furthermore, the
decreased CD8
+ T cell immunity to EBV was not due to a
primary defect in the function of CD8
+ T cells because
EBV specific cytotoxic CD8
+ T cell lines could be
generated normally from the PBMC of patients with MS.
Conclusion: This quantitative deficiency in CD8
+ T cell
immunity to EBV might be responsible for the accumula-
tion of EBV infected B cells in the brains of patients with
MS.
A large body of evidence indicates that multiple
sclerosis (MS) is an autoimmune disease
12but the
primary cause of MS and the other human chronic
autoimmune diseases is as yet unknown.
Epidemiological studies indicate that infection with
the Epstein–Barr virus (EBV) has a role in the
pathogenesis of MS.
3 In a meta-analysis of 13 case
control studies comparing EBV serology in patients
with MS and controls, 99.5% of patients with MS
were EBV seropositive compared with 94.0% of
controls, with EBV seronegativity having an ORMH
odds ratio of MS of 0.06 (exact 95% confidence
interval0.03to0.13; p,0.000000001).
3 Furthermore,
children with MS have an EBV seropositivity rate of
98.6% compared with 72.1% in age matched
controls.
4 These studies suggest that EBV infection
is a prerequisite for the development of MS.
EBV has the unique ability to infect, activate and
latently persist in B lymphocytes. When EBV
infects resting B cells, it drives them into activation
and proliferation independently of T cell help.
Usually, the proliferating infected B cells are
eventually eliminated by EBV specific cytotoxic
CD8
+ T cells but latently infected non-proliferating
memory B cells persist in the individual for life.
5
We have hypothesised that a genetically deter-
mined defect in the elimination of EBV infected B
cells by cytotoxic CD8
+ T cells might predispose to
the development of MS by allowing the accumula-
tion of EBV infected autoreactive B cells in the
CNS.
6 Recently it has been demonstrated that a
substantial proportion of the B cells and plasma
cells in the MS brain are infected with EBV.
7
Several studies have investigated T cell immu-
nity to EBV in MS and have yielded conflicting
results. Craig and colleagues
8 found that patients
with MS have decreased T cell control of the
number of immunoglobulin (Ig) secreting B cells
after in vitro infection with EBV. Using a panel of
five HLA-A2 restricted EBV peptides and one HLA-
B7 restricted EBV peptide, Ho ¨llsberg and collea-
gues
9 found an increased frequency of CD8
+ T cells
reactive to two immunodominant EBV epitopes in
patients with MS. However, another study
10 found
no differences in the CD8
+ T cell frequencies
between patients with MS and healthy controls
for seven HLA-B7 restricted EBV peptides, includ-
ing one of the peptides found by Ho ¨llsberg and
colleagues
9 to elicit an increased response. Using a
pool of 18 HLA class I restricted EBV peptides, Jilek
and colleagues
11 found an increased EBV specific
CD8
+ T cell response in patients with clinically
isolated syndromes but a normal response in
established MS whereas another study found that
patients with MS had an increased CD4
+ T cell
response to peptides derived from EBV nuclear
antigen-1 (EBNA1).
12
Studies on T cell immunity using selected EBV
peptides are limited by the fact that they do not
provide a measure of the total T cell response to
EBV, which encodes many different proteins. In
the present study we have investigated T cell
immunity to EBV in MS, focusing on the total T
cell response to EBV infected B cells using EBV
infected B cell lymphoblastoid cell lines (LCL) as
stimulators. LCL express not only the latent
proteins of EBV but also the lytic proteins,
13 14
owing to the fact that a proportion of the cells in
LCL are in the lytic phase of infection. Our specific
aims were to determine: (1) whether the frequency
of T cells specific for EBV infected B cells is
increased or decreased in patients with MS; (2)
whether EBV infected B cells of patients with MS
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+ T cells from HLA matched
healthy subjects; (3) whether EBV specific CD8
+ T cells
generated in vitro from patients with MS can kill EBV infected
B cells; and (4) whether there is a correlation between T cell and
antibody immunity to EBV.
METHODS
Subjects
Blood (60 ml) was collected from 34 EBV seropositive healthy
subjects and 34 EBV seropositive patients with MS following
informed consent. This study was approved by the Royal
Brisbane and Women’s Hospital Human Research Ethics
Committee and the University of Queensland Medical
Research Ethics Committee. All patients met the 2005 Revised
McDonald criteria for a diagnosis of MS.
15 The clinical course
was relapsing–remitting in 14 patients, secondary progressive in
11 and primary progressive in nine. Patients had not received
corticosteroids or immunomodulatory therapy for at least
3 months prior to venesection. Only five of the patients had
ever received interferon b, glatiramer acetate or immunosup-
pressant drugs, and in three of these the treatment had been
stopped at least 2 years before blood was collected for this
study. Disability was assessed using the Kurtzke Expanded
Disability Status Scale (EDSS)
16 and the MS Severity Score
(MSSS) was determined from the EDSS and disease duration.
17
The demographic and clinical details of the healthy subjects and
patients with MS are presented in table 1. Subjects were
Caucasian except for one healthy subject and two patients with
MS who were Asian.
Processing of blood samples
Blood (10 ml) was used for DNA extraction and HLA typing,
and 5 ml for serum collection. Peripheral blood mononuclear
cells (PBMC) were separated by density centrifugation, resus-
pended in complete RPMI (RPMI-C) with 10% dimethyl
sulphoxide (Sigma, St Louis, Missouri, USA) and cryopreserved
in liquid nitrogen. RPMI-C was prepared by supplementing
RPMI-1640 tissue culture medium (Invitrogen, Carlsbad,
California, USA) with 10% heat inactivated fetal calf serum
(Cambrex, Walkersville, Maryland, USA), 2 mM L-glutamine
(Lonza, Walkersville, Maryland, USA), 50 U/ml penicillin
(Invitrogen), 50 mg/ml streptomycin (Invitrogen) and 0.01 M
HEPES buffer (Lonza, Walkersville, Maryland, USA).
Antiviral antibodies
Serum samples were diluted in doubling dilutions ranging from
1/12.5 to 1/12800 and tested using enzyme linked immunosor-
bent assay (ELISA) kits (Inverness Medical, Brisbane, Australia)
to determine the titres of IgG specific for EBNA1 and EBV viral
capsid antigen (VCA).
HLA typing
Genomic DNA was extracted from 10 ml of heparinised blood
using NucleoSpin Blood XL DNA extraction kits (Macherey-
Nagel, Du ¨ren, Germany). Low resolution sequence specific
primer kits (Dynal Biotech, Oslo, Norway) were used to type for
HLA-A, HLA-B, HLA-DR, HLA-DQA and HLA-DQB.
Generation of LCL and assessment by flow cytometry
LCL were generated from each subject by incubating 50 000
washed PBMC with the B95-8 strain of EBV overnight in 1 ml
of RPMI-C supplemented with 2 mg/ml ciclosporin (Sigma).
LCL were cultured in this medium for 1 month followed by at
least another 2 months of culture in RPMI-C without ciclo-
sporin until confluent rapidly growing lines were obtained.
These LCL were flow cytometrically assessed after 3 months of
culture to confirm that they contained only CD19
+ B cells, with
no contaminating CD3
+ T cells, before being used in ELISPOT
assays, cytotoxicity assays or for the generation of LCL specific
T cell lines. To quantify HLA class I expression by LCL, healthy
log phase cultures of LCL were stained with R-PE labelled
antihuman HLA-ABC (BD Pharmingen, San Diego, California,
USA).
ELISPOT assays
To measure the total T cell response to EBV infected B cells, we
incubated PBMC with autologous LCL. PBMC were thawed
from liquid nitrogen storage and incubated in RPMI-C for 24 h
before use to allow re-expression of cell surface receptors. After
counting and assessment for viability by trypan blue staining,
PBMC were cultured in quadruplicate with either 50 000 or
5000 cells per well in 200 ml volumes of RPMI-C in the presence
of 50 000 autologous LCL or in the absence of LCL for 48 h.
Interferon c (IFNc) enzyme linked immunospot (ELISPOT)
assays were conducted using a commercially available kit
(Mabtech, Stockholm, Sweden), according to the manufac-
turer’s instructions. The average number of IFNc spot forming
cells (SFC) per well in the presence of PBMC and absence of
LCL, and the average number of SFC per well in the presence of
LCL and absence of PBMC were added together for each subject.
The sum of these backgrounds was subtracted from the average
number of SFC per well in the presence of both PBMC and LCL,
with the difference expressed as the number of LCL specific
IFNc SFC per 10
6 PBMC. The mean background for PBMC alone
was 7 (7) SFC per 10
6 cells in healthy subjects and 13 (19) SFC
per 10
6 cells in patients with MS, and the mean background for
LCL alone was 33 (53) SFC per 10
6 cells in healthy subjects and
73 (90) SFC per 10
6 cells in patients with MS. In some subjects
we also used the IFNc ELISPOT assay to measure the frequency
of PBMC specific for synthetic EBV peptides by incubating
200 000 PBMC per well with and without 10 mg/ml of each
peptide.
T cell cytotoxicity assays
Chromium release assays were performed to measure the killing
of LCL by a panel of five non-autologous HLA matched EBV
specific CD8
+ T cell clones derived from healthy subjects in
previous studies by SRB.
18 LCL were washed, labelled for 60 min
with 3.7610
6 Bq of
51Cr (Na2Cr3O4)a t3 7 uC and then washed
twice with medium. The
51Cr-labelled target cells (10
4 per well)
were mixed with T cells from HLA matched T cell clones at
effector:target ratios of 4:1 and 2:1 in 96 well round bottomed
plates in 200 ml volumes. After 5 h of incubation, 25 mlo f
supernatant from each well were counted in a b scintillation
Table 1 Characteristics of healthy subjects and patients
with MS
HC MS
n3 4 3 4
Female sex (n) 26 19
Mean age (years) 39.5 (9.9) 43.8 (11.8)
Mean age of onset of MS (years) 34.1 (10.9)
Mean duration of MS (years) 10.1 (7.6)
Mean EDSS 4.8 (2.4)
Mean MSSS 6.2 (3.0)
EDSS, Expanded Disability Status Scale; HC, healthy control
subjects; MS, multiple sclerosis; MSSS, MS Severity Score.
Research paper
J Neurol Neurosurg Psychiatry 2009;80:498–505. doi:10.1136/jnnp.2008.161018 499counter (Packard Instrument, Meriden, Connecticut, USA).
Maximum release and spontaneous release of
51Cr were
measured in wells containing target cells in the presence of
10% sodium dodecyl sulphate or medium alone, respectively.
The per cent specific lysis was calculated by the formula:
% specific lysis = (test release 2 spontaneous release)/
(maximum release 2 spontaneous release) 6100.
Generation and testing of EBV specific T cell lines
To generate EBV specific T cell lines, PBMC were incubated
with 10
6 irradiated (80 Gy) autologous LCL (stimulator to
responder ratio of 1:10) in RPMI-C without interleukin 2 (IL2)
in 24 well tissue culture plates. Eleven days later, each cell line
was restimulated with irradiated autologous LCL, and from day
13 the medium was supplemented with 20 U/ml recombinant
IL2. A third stimulation with irradiated autologous LCL was
given on day 22. Cultures were immunophenotyped by flow
cytometry and tested for cytotoxic capacity at day 40. The T
cell lines were assessed by flow cytometry to determine the
proportions of CD4
+CD3
+ T cells, CD8
+CD3
+ T cells and
CD16
+CD3
2/CD56
+CD3
2 NK cells using directly conjugated
antibodies (BD Pharmingen, San Diego, California, USA). The
cytotoxic capacity of the T cell lines was determined by 5 h
chromium release assays using autologous LCL and HLA
mismatched LCL as targets, with effector:target ratios of 20:1,
10:1, 5:1 and 2.5:1.
Statistical analysis
Statistical analyses were performed using SigmaStat 3.11.0
(Systat Software, Inc., San Jose, California, USA). For compar-
isons between patients with MS and healthy subjects when the
data were normally distributed, the means were compared using
the Student’s t test. If the data were not normally distributed,
the medians were compared using the Mann–Whitney rank
sum test. Differences between means or between medians were
considered significant if p(0.05. Means are presented as mean
Figure 1 Frequencies of T cells producing interferon c (IFNc)i n
response to autologous lymphoblastoid cell lines (LCL) and to individual
synthetic peptides derived from Epstein–Barr virus (EBV) proteins in an
EBV seropositive healthy subject (A) and an EBV seropositive multiple
sclerosis (MS) patient (B). Each peptide is represented by the first three
amino acids of its sequence. In the healthy subject (A), the highest
response to any peptide was against EPLPQGQLTAY, derived from the
EBV lytic cycle protein BZLF1 and restricted by HLA-B35, which was
carried by this subject. The next highest peptide response was against
HPVGEADYFEY, derived from the latent cycle protein EBNA1 and also
restricted by HLA-B35. The third highest response was against
TSLYNLRRGTALAI, derived from EBNA1 and restricted by HLA-DR1,
which was carried by this subject. The other peptides, proteins from
which they are derived and their HLA restriction elements are as follows:
GLC, GLCTLVAML from BMLF1, HLA-A2; RAK, RAKFKQLL from BZLF1,
HLA-B8; DEV, DEVEPLGHY from BMLF1, HLA-B18; RLR, RLRAEAQVK
from EBNA3A, HLA-A3; VFS, VFSDGRVAC from EBNA3A, HLA-A29;
RPP, RPPIFIRRL from EBNA3A, HLA-B7; FLR, FLRGRAYGL from
EBNA3A, HLA-B8; VEIT, VEITPYKPTW from EBNA3B, HLA-B44; IVT,
IVTDFSVIK from EBNA3B, HLA-A11; VMS, VMSNTLLSAW from latent
membrane protein 2, HLA-A25; NPK, NPKFENIAEGLRALL from EBNA1,
HLA-DR11; SDD, SDDELPYIDPNMEPV from EBNA3C, HLA-DR11; AEG,
AEGLRALLARSHVER from EBNA1, HLA-DR15; KTSL, KTSLTNLRRGTALA
from EBNA1, HLA-DR7; and PSM, PSMPFASDYSQGAFT from EBNA3C,
HLA-DR4. In the patient with MS (B), the highest response to any peptide
was against RPPIFIRRL, derived from the EBV latent cycle protein
EBNA3A and restricted by HLA-B7, which was carried by this patient. In
both subjects the sum of the responses to the 18 individual peptides
tested was much lower than the response to the LCL.
Figure 2 Frequencies of peripheral blood mononuclear cell (PBMC)
producing interferon c (IFNc) in response to autologous lymphoblastoid
cell lines (LCL) in 34 Epstein–Barr virus (EBV) seropositive healthy
subjects and 34 EBV seropositive patients with multiple sclerosis (MS).
The mean frequency in patients with MS (1573 (798) per 10
6 PBMC) was
significantly lower than the mean in healthy subjects (2326 (1314) per
10
6 PBMC) (p=0.006, heteroscedastic t test).
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anti-EBNA1 or anti-VCA IgG, we used the x
2 test with Yates’
correction as required. To measure the correlation between
data, the parametric Pearson product moment correlation was
used for normally distributed data, and the Spearman rank order
correlation was used for non-parametric data.
RESULTS
Patients with MS have decreased T cell immunity to EBV
In preliminary studies we used ELISPOT assays to determine
the frequency of PBMC producing IFNc in response to synthetic
peptides derived from a variety of EBV proteins and restricted
by HLA molecules commonly carried by patients with MS.
When analysing these experiments, three problems became
apparent. Firstly, the T cell responses to any given EBV peptide
could be compared only between those subjects who carried the
restricting HLA molecule. Secondly, the use of selected EBV
peptides did not provide a measure of the total T cell response
to EBV in any subject. Thirdly, the use of peptides bypasses the
normal physiological process of antigen processing. Thus a
person might have a high frequency of T cells producing IFNc in
response to an exogenously added synthetic EBV peptide which
is presented at a low density on the surface of EBV infected B
cells so that the infected B cells are poorly recognised by peptide
specific T cells.
19
To overcome these problems, we measured the frequency of
PBMC producing IFNc in response to autologous LCL. This
approach provides a direct measure of the aggregate T cell
response to EBV infected B cells in each subject and also allows
comparisons between subjects regardless of which HLA genes
are carried. Figure 1 shows that the sum of the responses to the
18 individual synthetic peptides tested is much lower than the
response to the LCL in a given subject. By extracting purified
populations of CD4
+ T cells, CD8
+ T cells and NK cells from
PBMC using immunomagnetic beads, we found that LCL
specific T cells were 5–7-fold more frequent in the CD8
+ T cell
population than in the CD4
+ T cell population and less frequent
again in the NK cell population (not shown).
We then measured the T cell reactivity against LCL in 34 EBV
seropositive healthy subjects and 34 EBV seropositive patients
with MS (fig 2). The specificity of this response as a measure of
EBV immunity was demonstrated by the fact that the
Table 2 HLA class I and class II typing
HLA class I HLA class II
HLA allele HC (n (%)){ MS (n (%)){ HLA allele HC (n (%)) MS (n (%))
A*01 9 (26.5) 6 (17.6) DRB1*01 7 (20.6) 7 (20.6)
A*02 16 (47.1) 11 (32.4) DRB1*15 12 (35.3) 18 (52.9)
A*03 10 (29.4) 11 (32.4) DRB1*16 0 (0.0) 2 (5.9)
A*11 4 (11.8) 7 (20.6) DRB1*03 9 (26.5) 7 (20.6)
A*23 5 (14.7) 1 (2.9) DRB1*04 13 (38.2) 6 (17.6)
A*24 2 (5.9) 6 (17.6) DRB1*11 5 (14.7) 3 (8.8)
A*25 2 (5.9) 2 (5.9) DRB1*12 1 (2.9) 2 (5.9)
A*26 1 (2.9) 0 (0.0) DRB1*13 7 (20.6) 5 (14.7)
A*29 2 (5.9) 0 (0.0) DRB1*14 2 (5.9) 0 (0.0)
A*30 1 (2.9) 1 (2.9) DRB1*07 8 (23.5) 6 (17.6)
A*31 0 (0.0) 3 (8.8) DRB1*08 2 (5.9) 2 (5.9)
A*32 2 (5.9) 3 (8.8) DRB1*09 0 (0.0) 0 (0.0)
A*33 1 (2.9) 1 (2.9) DRB1*10 1 (2.9) 2 (5.9)
A*36 0 (0.0) 2 (5.9)
A*68 1 (2.9) 2 (5.9) DQA1*01 26 (76.5) 28 (82.4)
A*74 1 (2.9) 0 (0.0) DQA1*02 8 (23.5) 7 (20.6)
A*92 1 (2.9) 0 (0.0) DQA1*03 14 (41.2) 6 (17.6)
DQA1*04 2 (5.9) 3 (8.8)
B*07 7 (20.6) 14 (41.2) DQA1*05 14 (41.2) 11 (32.4)
B*08 7 (20.6) 6 (17.6)
B*13 4 (11.8) 3 (8.8) DQB1*02 15 (44.1) 11 (32.4)
B*14 4 (11.8) 2 (5.9) DQB1*03 17 (50.0) 13 (38.2)
B*15 4 (11.8) 2 (5.9) DQB1*04 1 (2.9) 2 (5.9)
B*18 2 (5.9) 4 (11.8) DQB1*05 10 (29.4) 11 (32.4)
B*27 2 (5.9) 1 (2.9) DQB1*06 18 (52.9) 21 (61.8)
B*35 4 (11.8) 8 (23.5)
B*37 2 (5.9) 1 (2.9)
B*38 1 (2.9) 1 (2.9)
B*39 1 (2.9) 4 (11.8)
B*40 4 (11.8) 4 (11.8)
B*44 12 (35.3) 6 (17.6)
B*49 2 (5.9) 0 (0.0)
B*51 4 (11.8) 1 (2.9)
B*52 1 (2.9) 1 (2.9)
B*53 0 (0.0) 1 (2.9)
B*55 2 (5.9) 2 (5.9)
B*57 1 (2.9) 4 (11.8)
{Number (%) of subjects carrying each allele, either heterozygously or homozygously.
HC, 34 healthy control subjects; MS, 34 patients with multiple sclerosis.
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+ T cell clones from healthy
subjects
Subject
Per cent specific lysis of LCL by T cell clone
HLA-A3* RLRAEAQVK{
clone JC/RLR2
HLA-B7 RPPIFIRRL
clone JO/RPPI71
HLA-A11 AVFDRKSDAK
clone CM/AVF291
E:T=4:1 E:T=2:1 E:T=4:1 E:T=2:1 E:T=4:1 E:T=2:1
HC 2 42.3 30.2
HC 5 5.4 4.4
HC 9 17.3 15.2
HC 11 46.2 34.1 21.0 16.9
HC 14 62.8 49.5
HC 15 26.1 23.1 20.4 18.2
HC 16 37.2 29.5 49.4 50.7
HC 21 38.3 31.6 9.9 9.7
HC 25 31.4 31.5
HC 26 40.3 32.2
HC 30 9.4 4.9
HC 34 26.0 27.5
Mean HC 41.9 (11.1) 32.9 (8.1) 13.9 (6.5) 11.6 (6.1) 35.6 (12.3) 36.6 (12.4)
MS 143 62.8 47.2 31.5 25.1
MS 187 71.3 60.3 11.8 10.1
MS 188 25.4 21.8 53.7 52.2
MS 196 39.9 31.5 16.3 15.8
MS 200 37.5 33.8 8.5 6.5
MS 201 57.1 38.0
MS 212 13.7 12.8
MS 215 11.1 11.1 31.1 30.9
MS 329 4.4 1.6 12.6 14.6
MS 419 33.9 30.7 10.1 10.2
MS 442 45.9 35.8
MS 468 49.5 42.0
Mean MS 49.7 (13.1) 39.9 (9.9) 14.8 (8.6) 12.8 (7.3) 32.5 (20.6) 32.6 (18.9)
p Value{ 0.24 0.16 0.84 0.74 0.83 0.77
*HLA restriction element of T cell clone.
{EBV peptide recognised by T cell clone.
{Student’s t test for comparison between mean HC and mean MS.
1Similar results were obtained using another CD8
+ T cell clone specific for the same peptide.
EBV, Epstein–Barr virus; E:T, effector:target ratio; LCL, lymphoblastoid cell lines; Mean HC, mean (SD) in healthy control subjects;
Mean MS, mean (SD) in patients with multiple sclerosis.
Table 4 Phenotype and cytotoxicity of LCL specific T cell lines
Subject
Phenotype of T cell line (%)
Per cent specific lysis of LCL
Autologous LCL HLA mismatched LCL
CD4
+ CD8
+ NK E:T=20:1 E:T=10:1 E:T=20:1 E:T=10:1
HC 4 7.7 86.9 0.9 46.5 37.4 13.4 8.1
HC 12 16.1 85.3 1.1 40.2 36.2 6.3 6.0
HC 14 59.4 31.7 0.6 36.8 27.1 10.1 6.5
HC 24 29.5 67.2 2.8 54.3 49.4 19.1 15.1
HC 31 23.4 71.9 3.8 52.4 43.1 9.1 7.6
HC 32 47.8 45.2 0.7 49.0 40.9 6.1 5.5
Mean HC 30.6 (19.6) 64.7 (22.1) 1.0* 46.5 (6.9) 39.0 (7.5)
MS 192 60.9 38.8 1.0 17.0 7.1 21.7 25.1
MS 210 20.3 73.2 3.5 69.2 63.3 12.1 9.1
MS 211 45.3 54.8 0.5 39.3 29.5 2.3 3.7
MS 212 7.6 90.0 1.7 45.5 30.1 9.0 5.4
MS 215 40.5 60.1 1.1 46.3 35.4 5.4 2.1
MS 428 19.0 63.3 8.7 95.1 96.2 15.9 14.9
Mean MS 32.3 (19.9) 63.4 (17.3) 1.4* 52.1 (26.9) 43.6 (31.4)
p Value{ 0.89 0.91 0.70{ 0.64 0.74
*Median.
{Student’s t test for comparison between Mean HC and Mean MS.
{Mann–Whitney rank sum test for comparison of median per cent NK cells between HC and MS.
E:T, effector:target ratio; LCL, lymphoblastoid cell lines; Mean HC, mean (SD) in healthy control subjects; Mean MS, mean (SD) in
patients with multiple sclerosis.
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per 10
6 PBMC, which was much lower than the mean in EBV
seropositive healthy subjects. The mean LCL specific T cell
frequency in the EBV seropositive patients with MS was 1573
(798) per 10
6 PBMC, which was significantly lower than that in
EBV seropositive healthy subjects (2326 (1314) per 10
6 PBMC;
p=0.006) (fig 2). The mean LCL specific T cell frequency per
10
6 PBMC was 1635 (898) in patients with relapsing–remitting
MS, 1235 (437) in patients with secondary progressive MS and
1888 (897) in patients with primary progressive MS. The
frequency in female patients (1551 (900) per 10
6 PBMC) was
similar to that in male patients (1600 (677) per 10
6 PBMC;
p=0.86). There were no significant correlations between the
LCL specific T cell frequency and patient age, disease duration,
EDSS or MSSS. Interestingly, there was a significant correlation
between the T cell frequency and age of onset of MS (r=0.38;
p=0.028)—that is, the lower the T cell frequency the earlier the
onset of MS.
These results indicate that patients with MS have a decreased
T cell response to EBV infected B cells. Because EBV specific T
cell IFNc production correlates with EBV specific T cell
cytotoxicity,
20 this suggests that patients with MS have a
defective ability to eliminate EBV infected B cells. One possible
explanation for decreased CD8
+ T cell reactivity to LCL is
decreased HLA class I expression by LCL. The mean geometric
mean fluorescence intensity of HLA class I on LCL was 434
(173) in healthy subjects and 425 (173) in patients with MS
(p=0.82), showing that the decreased T cell reactivity to LCL in
patients with MS was not due to decreased HLA class I
expression on LCL and was most likely due to an absolute
decrease in the numbers of CD8
+ T cells reacting to LCL.
Decreased T cell immunity to EBV in MS is not explained by
differences in HLA genes
The results of HLA-A, HLA-B, HLA-DRB, HLA-DQA and HLA-
DQB typing are presented in table 2. The main differences
between patients with MS and healthy subjects were as
follows: patients with MS carried A*02 and B*44 less frequently,
and B*07 and DRB1*15 more frequently, than healthy subjects,
as previously described.
21 There was no significant difference in
the frequency of T cells producing IFNc against LCL between
HLA-A2
+ and HLA-A2
– healthy subjects, between HLA-A2
+ and
HLA-A2
2 patients with MS, between HLA-B7
+ and HLA-B7
2
healthy subjects, between HLA-B7
+ and HLA-B7
2 patients with
MS, between HLA-B44
+ and HLA-B44
2 healthy subjects,
between HLA-B44
+ and HLA-B44
2 patients with MS, between
HLA-DR15
+ and HLA-DR15
2 healthy subjects or between HLA-
DR15
+ and HLA-DR15
2 patients with MS, indicating that
differences in HLA genes carried by patients with MS and
healthy subjects do not account for the decreased T cell
response to LCL in patients with MS.
EBV infected B cells from patients with MS are normally
susceptible to killing by cytotoxic CD8
+ T cells
To determine whether EBV infected B cells from patients with
MS can be killed by EBV specific CD8
+ T cells, we used
chromium release assays to measure the killing of LCL by HLA
matched EBV specific CD8
+ T cell clones derived from healthy
subjects (table 3). Using a CD8
+ T cell clone specific for the
HLA-A3 restricted RLRAEAQVK peptide of EBNA3A,
22 we
found that the killing of LCL from HLA-A3
+ patients with MS
and healthy subjects was similar. With a CD8
+ T cell clone
specific for the HLA-B7 restricted RPPIFIRRL peptide of
EBNA3A,
22 the killing of LCL from HLA-B7
+ patients with MS
and healthy subjects was also similar. With a CD8
+ T cell clone
specific for the HLA-A11 restricted AVFDRKSDAK peptide of
EBNA3B,
23 the killing of LCL from HLA-A11
+ patients with MS
and healthy subjects was also similar. These results indicate
that EBV infected B cells from patients with MS can be killed by
EBV specific CD8
+ T cells just as readily as those from healthy
subjects. The results are also consistent with our finding of
normal HLA class I expression by LCL in patients with MS and
provide further evidence that the decreased T cell reactivity to
LCL is not due to an LCL abnormality.
Patients with MS can generate normal EBV specific cytotoxic
CD8
+ T cell lines in vitro
One possible explanation for the decreased frequency of LCL
specific T cells in patients with MS is a primary T cell defect. To
investigate this, we generated T cell lines from 10 healthy
subjects and 11 patients with MS by stimulating PBMC with
irradiated autologous LCL. The T cell lines from six healthy
subjects and six patients with MS specifically killed autologous
LCL but not HLA mismatched LCL (table 4). The EBV specific T
cell lines were composed predominantly of CD8
+ T cells in most
subjects. When tested against autologous LCL, the cytotoxic
capacity of the T cell lines was similar in healthy subjects and
patients with MS. These results indicate that, despite a lower
frequency of EBV specific T cells in patients with MS, EBV
specific cytotoxic CD8
+ T cell lines can be generated normally in
vitro from these patients. Thus the decreased frequency of
circulating LCL specific T cells cannot be explained by a primary
T cell defect.
Correlation between T cell and antibody immunity to EBV
Levels of anti-EBNA1 IgG and anti-VCA IgG were quantified by
titration of serum samples using ELISA (table 5). The geometric
mean titre of anti-EBNA1 IgG was higher in patients with MS
(1155) than in healthy subjects (720). The proportion of
individuals with a high titre (>1600) of anti-EBNA1 IgG was
also higher in the MS group than in the healthy control group
although the difference was not significant. The median
absorbance index for anti-EBNA1 IgG at a dilution of 1:200
was significantly higher in patients with MS (2.33) than in
healthy subjects (2.13; p=0.025). There was an inverse
correlation between the anti-EBNA1 IgG titre and the LCL
specific T cell frequency (rs=20.22, p=0.069) when the results
from healthy subjects and patients with MS were combined.
The geometric mean titre of anti-VCA IgG was similar in
patients with MS and healthy subjects, as was the proportion of
individuals with a titre >1600. There was no correlation
between the anti-VCA IgG titre and the LCL specific T cell
frequency.
DISCUSSION
In this study, we have shown that patients with MS have
decreased T cell immunity to EBV, as assessed by the frequency
of PBMC producing IFNc in response to autologous LCL. In
contrast to the use of synthetic EBV peptides as target antigens,
this approach provides a direct measure of the aggregate T cell
response to EBV infected B cells in each subject because it uses
each person’s natural antigen processing mechanisms to present
viral antigens at normal physiological concentrations on the
surface of their own EBV infected B cells and it represents the
total T cell response to all EBV antigens presented by all HLA
molecules on LCL in each subject. Furthermore, LCL stimulation
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to the lytic proteins.
13 14 Our finding of decreased T cell
immunity to EBV in MS is not a reflection of a generalised
depression in T cell immunity because patients with MS have
normal T cell responses to tetanus toxoid and concanavalin A
and increased responses to myelin antigens.
24
By studying the T cell response to LCL in purified populations
of CD4
+ T cells, CD8
+ T cells and NK cells, we have
demonstrated that CD8
+ T cells are the predominant population
responding to EBV infected B cells, with the frequency of EBV
specific CD8
+ T cells being 5–7-fold higher than the frequency of
EBV specific CD4
+ T cells, as previously reported.
20
Our finding of decreased T cell immunity to LCL in MS
differs from a previous small study on 11 patients which
reported a non-significant increase in the frequency of LCL
specific CD8
+ T cells, as determined by intracellular cytokine
flow cytometry.
25 The most likely explanation for this
discrepancy is the small sample size of that study. Our results
are consistent with an early study reporting that patients with
MS have decreased T cell control of the number of Ig secreting B
cells after in vitro infection with EBV.
8 A recent study using a
pool of 18 HLA class I restricted EBV peptides in ELISPOT
assays found an increased EBV specific CD8
+ T cell response in
patients with clinically isolated syndromes but a normal
response in established MS.
11 The results of that study are
difficult to interpret because it is likely that in any given subject
only a minority of the peptides in the peptide pool were
restricted by HLA class I alleles carried by the subject. Thus the
T cell response to the pool of peptides might have been
composed largely of responses that have no in vivo relevance. It
is noteworthy that the mean frequency of T cells responding to
the pool of peptides in healthy subjects in that study was only
5% of the mean frequency of LCL specific T cells in healthy
subjects in our study.
We have shown that the decreased CD8
+ T cell response to
LCL in MS is not due to decreased HLA class I expression on
the LCL and that LCL from patients with MS can be killed
normally by HLA matched EBV specific cytotoxic CD8
+ Tc e l l
clones from healthy subjects. We have also shown that
differences in HLA genes carried by patients with MS and
healthy subjects do not account for the decreased T cell
response to LCL in MS. In addition, we have demonstrated
that the decreased CD8
+ T cell response to EBV infected B cells
is not caused by a primary defect in the function of CD8
+ T
cells because EBV specific cytotoxic CD8
+ T cell lines could be
generated normally in vitro from PBMC of patients with MS.
One possible explanation for the decreased CD8
+ Tc e l l
immunity to EBV in MS is impaired priming of EBV specific
CD8
+ T cells by dendritic cells. A limitation of our study is
that we have not determined whether the decrease in CD8
+ T
cell immunity to EBV is accompanied by a decrease in CD8
+ T
cell immunity to other infectious agents. Further studies will
be required to investigate this.
Our finding of an elevated anti-EBNA1 IgG titre in patients
with MS is consistent with previous reports.
25–27 We also
observed an inverse correlation between the anti-EBNA1 IgG
titre and the anti-LCL T cell frequency, suggesting that the
elevated anti-EBNA1 IgG titre might be a consequence of
decreased CD8
+ T cell immunity to EBV. Prospective studies of
blood samples collected before the onset of MS have shown that
elevated IgG reactivity to EBNA1 increases the risk of
developing MS.
28–30
A fundamental question is whether the decreased frequency
of EBV specific T cells in the blood is the cause or effect of the
accumulation of EBV infected B cells in the CNS in MS,
7 or a
combination of both. Some of the decrease might be due to
sequestration of EBV specific CD8
+ T cells in the CNS. CD8
+ T
cells have been shown to be present in the CNS in proportion to
the number of EBV infected B cells
7 but it is not known whether
these CD8
+ T cells are specific for EBV and whether they can
recognise and kill EBV infected B cells in the CNS. If the
decreased frequency of LCL specific T cells in the blood were to
be attributed solely to sequestration within the CNS, it would
beg the question why EBV infected B cells accumulate in the
CNS in the first place and why are they not eliminated by EBV
specific CD8
+ T cells, given that we have shown that EBV
infected B cells of patients with MS can be killed by their own
EBV specific CD8
+ T cells. We suggest that the most likely
scenario is that a genetically determined quantitative deficiency
in the generation of EBV specific CD8
+ T cells in vivo allows the
accumulation of EBV infected B cells in the CNS in MS and that
a vicious circle then ensues whereby the inherently deficient
CD8
+ T cell response is further compromised by T cell
exhaustion
31 as a result of the persistent high EBV load in the
CNS. It could be argued that the decrease in EBV specific CD8
+
T cell immunity in patients with MS reported here is of an
insufficient degree to lead to the development of MS. However,
in non-linear dynamic systems, such as those commonly
occurring in biology and medicine, small changes in the initial
condition of a system can produce dramatic changes in long
term behaviour, sometimes referred to as the ‘‘butterfly
effect’’.
32 33 Our finding that lower LCL specific T cell
frequencies were associated with earlier age of onset of MS
suggests that the more severe the defect in EBV specific T cell
immunity the sooner MS will develop after primary EBV
infection. EBV specific CD8
+ T cells can also be sequestered in
the bone marrow
34 but there is no reason to believe that this
should occur to a greater extent in patients with MS than in
healthy subjects.
In conclusion, the quantitative deficiency in CD8
+ T cell
immunity to EBV reported in the present study might
predispose to the development of MS by allowing the
accumulation of EBV infected autoreactive B cells in the
CNS.
6 Boosting CD8
+ T cell immunity to EBV by vaccination
or by transferring EBV specific cytotoxic CD8
+ T cells may be
beneficial in preventing and treating MS.
Table 5 Titres of anti-EBNA1 IgG and anti-VCA IgG in serum
Titre
Anti-EBNA1 IgG Anti-VCA IgG
HC (n (%)) MS (n (%)) HC (n (%)) MS (n (%))
50 2 (6.1) 0 (0.0) 1 (3.0) 0 (0.0)
100 1 (3.0) 0 (0.0) 2 (6.1) 0 (0.0)
200 5 (15.2) 3 (8.8) 1 (3.0) 1 (2.9)
400 6 (18.2) 6 (17.6) 0 (0.0) 4 (11.8)
800 7 (21.2) 7 (20.6) 5 (15.2) 4 (11.8)
1600 6 (18.2) 10 (29.4) 9 (27.3) 15 (44.1)
3200 2 (6.1) 4 (11.8) 14 (42.4) 8 (23.5)
6400 4 (12.1) 4 (11.8) 1 (3.0) 1 (2.9)
12800 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9)
GMT 720 1155 1440 1536
n (%) titre >1600 12 (36.4) 18 (52.9) 24 (72.7) 25 (73.5)
p Value* 0.17 0.94
*x
2 test comparing proportions of HC and MS subjects with titre >1600.
EBNA1, Epstein–Barr virus nuclear antigen 1; GMT, geometric mean titre; HC, 33
healthy control subjects; MS, 34 patients with multiple sclerosis; VCA, viral capsid
antigen.
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